Discovering therapeutic antibodies designed by nature

Scientific advisory board strengthened with new high profile appointments

AIMM Therapeutics Significantly Strengthens Scientific Advisory Board with High Profile Appointments

June 21, 2013

Bob Löwenberg (Erasmus MC), John Mendelsohn (MD Anderson), and Hidde Ploegh (Whitehead Institute) to join AIMM SAB

AMSTERDAM — AIMM Therapeutics, a therapeutic antibody company, today announced the appointments of Bob Löwenberg, MD, PhD, John Mendelsohn, MD, and Hidde Ploegh, Ph.D. to the company’s Scientific Advisory Board (SAB).

AIMM’s SAB oversees the company’s therapeutic antibody pipeline, including antibody target identification and validation, second generation antibody formats, and selection of candidate therapeutic antibodies for preclinical development and clinical proof of concept studies. AIMM-therapeutics is currently expanding its programs in the areas of cancer and autoimmune- and inflammatory diseases.

“The world renowned expertise in oncology, immunology and biologics of our new SAB members will allow us to more rapidly leverage our technology platforms in cancer and autoimmune and inflammatory diseases,” said Dr. Jan de Vries, AIMM’s CEO. “AIMM is expanding its current pipeline with innovative, second generation antibodies using its AIMSelect™, AIMProve™ and AIMLink™ technology platforms. “

Dr Bob Löwenberg is Chairman of the Department of Hematology at the Erasmus University Medical Center in Rotterdam, the Netherlands. Prior to that he was the Scientific Director of the Daniel den Hoed Cancer Center in Rotterdam. Dr Löwenberg is internationally renowned for his pivotal contributions to the diagnosis and treatment of acute myeloid leukemia. Presently he serves as editor in chief of Blood, the journal of the American Society of Hematology.

Dr. Mendelsohn is an internationally recognized leader in cancer research and cancer therapy. He discovered Centuximab (Erbitux), an antibody directed against the epidermal growth factor receptor, and directed the first clinical trials that led to its approval by the US Food and Drug Administration for the treatment of colon cancer in 2004, and head-and-neck cancer in 2006. Dr Mendelsohn recently stepped down as president of the MD Anderson Cancer Center in Houston, Texas. He remains on the faculty as the co-director of the Sheik Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.

Dr. Hidde Ploegh is one of the world’s leading immunologists. He is a member of the Whitehead Institute for Biomedical Research, and Professor of Biology at the Massachusetts Institute of Technology, both in Cambridge, Massachusetts. Previously he held the Mallinckrodt Chair of Immunopathology at Harvard University, and was director of the graduate program for immunology at Harvard Medical School. He held leadership positions at the Netherlands Cancer Institute in Amsterdam, and at the University of Cologne’s Institute of Genetics.

Drs Mendelsohn, Löwenberg and Ploegh join Drs Menno de Jong and Tom van der Poll, both of the Academic Medical Center at the University of Amsterdam, and Ton Schumacher of the Netherlands Cancer Institute.

About AIMM Therapeutics

AIMM Therapeutics (AIMM) is a leading antibody company that based on its synergistic, state-of-the-art antibody technology platform develops high affinity human monoclonal antibodies from immortalized and selected B cells of individuals who produce antibodies with high therapeutic value. AIMM antibodies can be further affinity matured in a proprietary process that does not require molecular engineering. AIMM has a broad product pipeline targeted at pathogenic viruses and bacteria, and is expanding its pipeline with drug candidates for cancer and inflammatory diseases.

Contacts

Jan de Vries, CEO
AIMM Therapeutics
Tel: +31 (0)20 5662145

or

Capricorn One

Hans Herklots
+41 79 598 7149

Managing Director

capricorn1@bluewin.ch